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Although allogeneic hematopoietic cell transplantation (HCT) is an expensive treatment for hematological
disorders, little is known about the ﬁnancial consequences for the patients who undergo this procedure. We
analyzed factors associated with its ﬁnancial burden and its impact on health behaviors of allogeneic HCT
recipients. A questionnaire was retrospectively mailed to 482 patients who underwent allogeneic HCT from
January 2006 to June 2012 at the Mayo Clinic, to collect information regarding current ﬁnancial concerns,
household income, employment, insurance, out-of-pocket expenses, and health and functional status. A
multivariable logistic regression analysis identiﬁed factors associated with ﬁnancial burden and treatment
nonadherence. Of the 268 respondents (56% response rate), 73% reported that their sickness had hurt them
ﬁnancially. All patients for whom the insurance information was available (missing, n ¼ 13) were insured.
Forty-seven percent of respondents experienced ﬁnancial burden, such as household income decreased by
>50%, selling/mortgaging home, or withdrawing money from retirement accounts. Three percent declared
bankruptcy. Younger age and poor current mental and physical functioning increased the likelihood of
ﬁnancial burden. Thirty-ﬁve percent of patients reported deleterious health behaviors because of ﬁnancial
constraints. These patients were likely to be younger, have lower education, and with a longer time since HCT.
Being employed decreased the likelihood of experiencing ﬁnancial burden and treatment nonadherence due
to concern about costs. A signiﬁcant proportion of allogeneic HCT survivors experience ﬁnancial hardship
despite insurance coverage. Future research should investigate potential interventions to help at-risk patients
and prevent adverse ﬁnancial outcomes after this life-saving procedure.
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Financial hardship and concern about medical costs
are increasingly reported after medical treatment [1-4].
Extremely severe ﬁnancial outcomes, such as bankruptcy,
have been reported in cancer patients [5-7]. Studies have also
reported the adverse impact of ﬁnancial concerns on quality
of life and treatment adherence [1-4,8-10]. Although part of
the ﬁnancial burdenmay be due to high out-of-pocket (OOP)
costs, a decrease in household income due to loss of
employment and other nonmedical costs also adds to thedgments on page 1381.
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14.05.011ﬁscal distress for most households. The problem is further
compounded for allogeneic hematopoietic cell trans-
plantation (HCT) survivors because of prior treatments, long
hospital stays, prolonged intensive follow-up, living away
from home to relocate near to the transplantation center for
at least the ﬁrst 3 months after HCT, extended period of work
loss for patient and caregiver, and occurrence of chronic
medical problems, such as chronic graft-versus-host disease
(GVHD) and late complications. In an online survey of 369
HCT survivors, 42% were concerned about health insurance
and 30% reported ﬁnancial problems [11].
Only a few studies have attempted to describe the OOP
costs in this patient population [12-14]. To the best of our
knowledge, no studies have described the overall ﬁnancial
experienceof allogeneicHCTrecipientsor examined, indetail,
the factors associatedwith adverse ﬁnancial consequences of
this expensive, resource-intensive procedure. We conductedTransplantation.
Figure 1. Study Participation Flowchart. HCT, hematopoietic cell transplantation.
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acterize the subjective and objective ﬁnancial burden in
allogeneic HCT survivors. We also sought to describe the
impact of ﬁnancial burden on health behaviors and evaluate
the risk factors for objective ﬁnancial burden and treatment
nonadherence due to concern about medical costs.
PATIENTS AND METHODS
All adult patients who had an allogeneic HCT performed between
January 1, 2006 to June 30, 2012 at 1 of the 3 Mayo Clinic sites (Rochester,
Arizona, and Jacksonville) and who were reported to be alive, with a current
mailing address available at the time of the survey, were included. The study
was approved by the institutional review board at Mayo Clinic in Arizona.
Because of the lack of a validated instrument, a 25-item questionnaire
was designed to gather information about self-reported subjective and
objective ﬁnancial burden along with OOP expenses, medication copay-
ments, and sociodemographic information, such as race and ethnicity, ed-
ucation level, employment status, insurance, and household income (a copy
of the questionnaire attached, Supplementary Data). Information about
concerns regarding the cost of medical care leading to potentially delete-
rious health behaviors was also collected. The survey was designed based on
a literature review with the help of experts from the survey research center
at Mayo Clinic, Rochester. A formal patient pilot was not performed, but
feedback was collected from a small group of transplantation physicians and
nurse coordinators regarding clarity of the questions. Information collected
on the survey represented the patients’ status at time of survey completion.
Self-administered questionnaires were mailed to study patients in
December 2012 and were re-sent if a response was not received within
4 weeks of the initial mailing. Age, sex, and information about the disease
and HCT were available from the clinical research database. Race and
ethnicity data was retrieved from the clinical database for comparison be-
tween the respondents and nonrespondents, though in the multivariateanalysis, self-reported race/ethnicity obtained from the questionnaire was
used. Median household incomewas inferred from zip codes, using the 2010
census data, to compare the socioeconomic status between respondents and
nonrespondents [15].Study Variables
Race/ethnicity was categorized as Non-Hispanic whites, Hispanics, and
non-whites. Income was divided into 2 categories (<$2000/month and
>$2000/month), as $2000/month is the closest to the federal poverty
guideline ﬁgure for a 4-person household [16]. Education level was cate-
gorized as “high school or less,” “some college/associate degree,” or “4-year
degree or higher.” Employment was divided into 4 main categories:
employed, unemployed, retired, and medical disability. Primary health in-
surance was divided into 4 categories: private, Medicaid, Medicare, and
others, including Tricare, Indian Health Services, and Veterans’ Affairs.
Medicare information was further distinguished as Medicare with or
without a supplemental plan, depending on if the patient checked “insur-
ance purchased directly” or speciﬁed a supplemental plan in “others”
category, in addition toMedicare. Health insurance coveragewas considered
to be poor if the insurance company had denied coverage for part of treat-
ment “sometimes” or “often,” or if the patients answered “disagree or
strongly disagree” to the question about being satisﬁed with insurance
coverage for transplantation-related costs. All the above variables were
obtained from the survey and reﬂect the status at the time of questionnaire.
Self-reported variables were used in the analysis, as it has been suggested
that, relative to medical records and administrative claims data, self-
reported data are valid and maybe more accurate. In the area of race and
ethnicity data quality, for example, our research has shown self-report data
to be superior to the data ascertained from claims data, largely because of
high levels of missing or unknown race/ethnicity in the latter [17]. Similarly,
self-reported insurance status is commonly used as the source of national
health insurance, uninsurance, and underinsurance estimates by re-
searchers and health policy makers [18].
Table 1
Respondent and Nonrespondent Characteristics
Characteristic Nonrespondents
(n ¼ 214)
Respondents
(n ¼ 268)
P Value
Age at transplantation,
median (range), yr
47 (18-72) 55 (20-71) <.0001*
Gender .73y
Female 102 (48%) 132 (49%)
Male 112 (52%) 136 (51%)
Race/ethnicity .0005y
Non-Hispanic white 175 (82%) 246 (92%)
Non-white 16 (7%) 13 (5%)
Hispanics 23 (11%) 7 (3%)
Median income (derived
from zip code analysis)
$51,958 $55,421 .09*
Type of donor .54y
Unrelated 115 (54%) 136 (51%)
Related 99 (46%) 131 (49%)
Disease .18y
ALL 36 (17%) 38 (14%)
AML 85 (40%) 95 (35%)
CML 15 (7%) 10 (4%)
Hodgkin’s 5 (2%) 2 (1%)
MDS/MPN 34 (16%) 56 (21%)
MM 3 (1%) 8 (3%)
NHL/CLL 29 (14%) 47 (17%)
Nonmalignant 7 (3%) 12 (5%)
Disease riskz .09y
High 33 (16%) 30 (11%)
Intermediate 73 (34%) 118 (44%)
Low 101 (47%) 108 (40%)
Nonmalignant 7 (3%) 12 (5%)
Conditioning .009y
Reduced intensity 99 (46%) 156 (58%)
Myeloablative 115 (54%) 112 (42%)
Graft source .38y
Bone marrow 22 (10%) 25 (9%)
Peripheral blood 190 (89%) 236 (88%)
Cord 2 (1%) 7 (3%)
Acute GVHD (grade II-IV) 109 (83%) 114 (80%) .53y
Chronic GVHD 61 (29%) 58 (22%) .08y
Follow-up time, median
(range), yr
2.2 (.6-6.9) 2.3 (.7-6.7) .96*
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leu-
kemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syn-
drome; MPN, myeloproliferative neoplasms; MM, multiple myeloma; NHL,
non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia.
Data presented are n (%), unless otherwise indicated.
* Wilcoxon rank-sum test.
y Chi-square test.
z Disease risk: high: leukemia/lymphoma/myeloma not in remission,
chronic myelogenous leukemia (accelerated phase/blast crisis), and mye-
lodysplastic syndrome (refractory anemia with excess blasts in trans-
formation); low: chronic myelogenous leukemia (chronic phase),
myelodysplastic syndrome (refractory anemia/refractory anemia with
ringed sideroblasts), and acute leukemia in ﬁrst remission; and intermedi-
ate: all others.
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performance status and activity level, measured by the Medical Outcomes
Study Short Form-12, included in the questionnaire [19]. The scoring on this
survey is norm based, with a general population mean score of 50 and a
standard deviation of 10. Higher scores indicate better functional status.
Study Outcomes
Subjective ﬁnancial burden reﬂected the patients’ perceptions about
their ﬁnancial condition. It was assessed through responses to selective
questions adapted from the Material Capital Subscale developed by Head
and Faul to measure the socioeconomic well-being of cancer patients
(question 2 in the questionnaire attached, Supplementary Data, line items
16,18, 19, 20, 22, 24) [20]. Objective ﬁnancial burden referred to the tangible
impact that the transplantation had on patients’ ﬁnancial condition and was
reﬂected by a decrease in household income by >50%, selling/second
mortgage on home, withdrawing money from retirement accounts, or
declaring bankruptcy to pay for medical bills. This was a dichotomous
outcome and was operationally deﬁned by the patient reporting at least 1 of
the above. If the patient did not mark any of the above, they did not expe-
rience any (objective) ﬁnancial burden. Treatment nonadherencewas deﬁned
as a response of “sometimes” or “often” to at least 1 of the questions, asking if
the respondent had “cut back on the prescribed medications that you take,”
“not purchased a prescription medication,” “avoid making appointments to
see your doctor,” “not use medically related service,” or “not have a medical
test performed” due to “concern about medical costs.” This was also a
dichotomous outcome and an afﬁrmative response to any of the above
questionswas considered sufﬁcient for identifying treatment nonadherence.
Statistical Analysis
Differences between respondents and nonrespondents were deter-
mined using Wilcoxon rank-sum or chi-square test. The outcome of interest
was the objective ﬁnancial burden. A logistic regression model was used to
assess the factors such as age, gender, physical and mental functioning (<1
standard deviation from general population mean), disease and trans-
plantation characteristics, and socioeconomic variables, including race/
ethnicity, education, employment, and insurance associated with the cur-
rent objective ﬁnancial burden. In checking for collinearity between the
sociodemographic variables, we found that employment and insurance
were highly associated (P < .0001 from chi-square test of association), so
only 1 of themwas retained in the model. Because some groups of insurance
(Medicaid, VA/Tricare/others) were not well represented in our sample,
which would have affected the results of logistic regression, we used
employment status. Time from transplantation was also included in the
model. The univariate analysis was performed ﬁrst, and a variable with the
overall P value <.20 was considered in the model selection. Backward
eliminationwas then used and any variable with the overall P value<.15 was
retained in the multivariable model. The adjusted odds ratio and 95% con-
ﬁdence interval were reported. Because age is closely integrated with the
employment status, it was forced into the multivariate model for ﬁnancial
burden to address the possible confounding between age and retirement.
The other outcome of interest was treatment nonadherence due to concern
about medical costs. A similar approach as abovewas applied to evaluate the
factors associated with treatment nonadherence. For both the models, we
checked the possible 2-way and 3-way interaction terms between the ﬁnal
variables in the multivariate model, and we found that none of the inter-
action terms were statistically signiﬁcant. Hence, only the main effects were
included in the model.
RESULTS
Baseline Characteristics
A total of 834 patients underwent allogeneic HCT from
January 1, 2006 to June 30, 2012 at the 3 Mayo Clinic sites. Of
the 482 eligible patients who were sent the survey, 268
returned the completed questionnaire (response rate 56%)
(Figure 1). Table 1 summarizes the clinical characteristics
of the respondents versus nonrespondents. The non-
respondents were likely to be younger, Hispanics/non-white,
and to have received myeloablative conditioning. There were
no signiﬁcant differences in disease type, disease risk, donor
type, presence of acute or chronic GVHD, median household
income, and duration of median follow-up between the 2
groups. Sixteen percent of the respondents were less than
1 year, 53% were 1 to 3 years, and the remaining were greater
than 3 years from HCT.Table 2 describes the socioeconomic proﬁle of the re-
spondents. Insurance information was available for 255 pa-
tients and all of themwere insured. Although 69% of patients
reported being employed or at school full-time before HCT,
only 29% reported similar status after HCT. Eight percent of
patients were reported to be on medical disability before
HCT, and 31% were after HCT. Although a majority of the
respondents (72%) reported current household income
>$2000 per month,10% had amonthly income level<$1000.
Median physical and mental component score, as derived
from Medical Outcomes Study Short Form-12, were 36.8
(interquartile range, 29.3 to 49.0) and 53.1 (interquartile
range, 42.1 to 57.1), respectively, indicating poor physical
functioning but preserved mental functioning, compared
with general population.
Table 2
Socioeconomic Indicators for Respondents (n ¼ 268)
Indicator n (%)
Highest education (missing, n ¼ 23)
High school or less 39 (16%)
Some college/associate degree 94 (38%)
Four-yr degree or higher 112 (46%)
Current employment (missing, n ¼ 14)
Full-time work/school 70 (29%)
Part-time work/school 33 (14%)
Unemployed 11 (5%)
Retired 49 (20%)
Medical disability 75 (31%)
Homemaker 3 (1%)
Current monthly income (missing, n ¼ 16)
<$1000/mo 25 (10%)
$1000-$2000/mo 46 (18%)
>$2000/mo 181 (72%)
Insurance (missing, n ¼ 13)
Medicare only 16 (7%)
Medicare þ supplement 67 (26%)
Medicaid 10 (4%)
Tricare/Indian Health Service/Veterans Affairs/others 11 (4%)
Private only 151 (59%)
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Overall, 80% of the patients reported subjective ﬁnancial
burden, whereas 47% of the patients had objective ﬁnancial
burden (Table 3A). There was only a fair agreement between
patients’ subjective and objective ﬁnancial burden (kappa
coefﬁcient .28 [95% conﬁdence interval, .19 to .37]). OOP costs
for 3 months were above $2000 for 38% patients and above
$5000 for 12% patients. Seventy-one percent of patients re-
ported that they had copayments for prescriptions, with a
median monthly copayment of $100 (range, 0 to $3000).
Table 3B shows the distribution of OOPs/median prescription
copayments, change in employment status from HCT to
current time, and subjective and objective ﬁnancial burden
for patients at different times after HCT.
Current employment status and physical and mental
functioning were signiﬁcantly associated with objective
ﬁnancial burden in the univariate analysis and remained
signiﬁcant in the multivariate analysis (Table 4). Even though
agewas not signiﬁcant in the univariate analysis, when it was
forced in the model, it emerged as signiﬁcant in the multi-
variate analysis, with younger patients being more likely
to report ﬁnancial burden. None of the disease orTable 3A
Treatment-Related Financial Burden in Respondents
Subjective Financial Burden: n (%)
Agreement (answered agree/strongly agree)
I believe that being sick has hurt me ﬁnancially (n ¼ 266) 195 (73%)
I have to pay more for my medical care than I can
afford (n ¼ 264)
86 (33%)
The medicines I need are too expensive for me (n ¼ 267) 81 (30%)
Disagreement (answered disagree/strongly disagree)
I have enough money to take care of my health care
needs (n ¼ 268)
85 (32%)
I am able to pay my medical bills (n ¼ 268) 59 (22%)
I am able to make enough money to pay for my health
care (n ¼ 267)
93 (35%)
Objective Financial Burden: n (%)
Household income decreased by more than 50% (n ¼ 254) 65 (26%)
Reﬁnance/second mortgage on your home (n ¼ 268) 22 (8%)
Sell your home (n ¼ 268) 3 (1%)
Declare bankruptcy (n ¼ 268) 7 (3%)
Withdraw money from retirement accounts (n ¼ 268) 68 (25%)transplantation-related characteristics were associated with
ﬁnancial burden.
Thirty-six percent of patients reported poor insurance
coverage, which was also a risk factor for ﬁnancial burden
(56% of those with poor coverage, compared with 41% of
those without poor coverage, had objective ﬁnancial burden;
P¼ .02). Insurance had denied coverage for part of treatment
for 32% of the patients at some point during or after their
HCT. Coverage denials were usually for medications (espe-
cially voriconazole and valacyclovir), GVHD-related tests or
treatments (extracorporeal photopheresis, scleral lenses, and
liver biopsy) or other tests, eg, positron emission tomogra-
phyecomputed tomography scans for restaging.
Impact of Costs on Health Behaviors
Nineteen percent of patients reported cutting back or not
purchasing prescription medications because of concern
about medical costs, and 21% reported not making a physi-
cian appointment or having a medical test performed. Use of
a medical service, eg, physical therapy, was deferred by 28%
of the respondents as a result of cost burden.
Table 5 outlines the predictors for nonadherence to
medical management because of concerns of medical costs.
Patients younger in age, those with lower educational level
and lower physical functioning, and those who were more
than 3 years out from HCT were more likely to exhibit
potentially deleterious health behaviors because of concerns
of medical costs, but being employed was protective for
economically motivated treatment nonadherence.
DISCUSSION
Financial concerns are emerging as 1 of the important
concerns in medical care continuum. In this study, we found
that recipients of allogeneic HCT experience substantial
ﬁnancial burden, with a few suffering from severe outcomes,
such as bankruptcy, being forced to sell their homes, or using
their retirement savings. The study indicates that “ﬁnancial
toxicity” is an under-recognized complication of HCT, anal-
ogous to more frequently described late medical complica-
tions. Similar to medical complications, ﬁnancial toxicity
may have the potential to compromise the health of patients
who undergo HCT. Younger patients and patients with lower
physical and mental functioning were at greatest risk for
adverse ﬁnancial consequences of HCT, whereas being
employed appeared to be protective for experiencing
objective ﬁnancial burden. Concern about medical costs
leading to deleterious health behaviors was seen in one third
of the study population and was more common in younger
patients, those with a lower level of education, and those
who were retired or on disability.
Another important aspect of ﬁnancial consequences after
HCT is that they do not end after the ﬁrst 3 months of HCT;
instead, they continue through the survivorship phase
because of the long-term complications. Although in our
study increasing time from transplantation was not signiﬁ-
cantly associated with a higher report of objective ﬁnancial
burden, increasing ﬁnancial difﬁculty with increasing time
from transplantationwas expressed by some patients in their
narrative comments when answering the questionnaire.
Increasing time from transplantation also increased the
likelihood of economically motivated treatment non-
adherence. Whereas most patients have insurance options
that may provide adequate coverage around the time of HCT
(for the pretransplantation phase and subsequent 3 months),
we hypothesize that ﬁnancial issues may become more
Table 3B
Financial Burden and Employment Changes Across Different Time Periods after HCT
Less Than One-Yr
Survivors (n ¼ 39)
One to ThreeeYear
Survivors (n ¼ 125)
More Than Three-Yr
Survivors (n ¼ 73)
P Value
Out-of-pocket costs for past 3 mo (n ¼ 226) .09*
<$2000 19 (50%) 78 (65%) 47 (70%)
$2000-$5000 14 (37%) 26 (21%) 17 (25%)
>$5000 5 (13%) 17 (14%) 3 (5%)
Monthly prescription copayments (n ¼ 171), median (range) $150 (20-1530) $100 (0-3000) $88 (0-2500) .04y
Change in employment statusz (n ¼ 210) .29*
Employed to employed 18 (50%) 45 (41%) 28 (44%)
Employed to retired/disability 11 (31%) 33 (30%) 19 (30%)
Employed to unemployed 1 (3%) 3 (3%) 3 (5%)
Unemployed to employed 0 (0%) 0 (0%) 3 (5%)
Unemployed to retired/disability 0 (0%) 1 (1%) 0 (0%)
Unemployed to unemployed 1 (3%) 1 (1%) 0 (0%)
Retired/disability to unemployed 1 (3%) 0 (0%) 1 (2%)
Retired/disability to retired/disability 4 (11%) 27 (25%) 10 (16%)
Subjective ﬁnancial burden 31 (80%) 101 (81%) 57 (78%) .90*
Objective ﬁnancial burden 20 (51%) 55 (44%) 36 (49%) .64*
* Chi-square.
y Kruskal Wallis.
z Employment before HCT to current.
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reimbursements, life-time caps, and loss of coverage, espe-
cially if dependent on employment.
There is no doubt that the increasing cost of health care
translates into an ever-increasing burden on the health care
system and for individual patients. HCT as an expensive
modality is utilized by a highly selective group of patients
based on the referral practices. Nearly all of our study pop-
ulation was insured, which is not surprising as lack of in-
surance coverage was a major cause of nonreferral for HCT
[21]. High OOP costs, medical copayments, and poor
coverage/insurance denials may still lead to ﬁnancial burden
in patients, despite being insured. With extensive pretreat-
ment, some patients may have already exhausted much of
their ﬁnancial resources even before coming to HCT. Our
study raises the question of whether the pretransplantation
evaluation should include discussion about the ﬁnancial
impact and if consent for HCT should include the possibility
of ﬁnancial toxicity, similar to what has been suggested by
Ubel et al. recently [22]. It also provides useful information to
payers, employers, and policy makers to plan steps to ensure
access to affordable multidisciplinary post-HCT care.
The complex inter-relationship between quality of life
and ﬁnancial burden in HCT recipients is an area of active
investigation. Hamilton et al. have reported persistent
ﬁnancial demands and employment complications after
HCT to be detrimental to survivors’ physical and psycho-
logical well-being [10]. Lower household income has been
shown to relate to adverse psychological outcomes [2,23].
Although it is likely that poor ﬁnancial outcomes would
precipitate increased psychosocial distress and impaired
quality of life in allogeneic HCT survivors, our study, which
did show signiﬁcant association between poor mental and
physical functioning and ﬁnancial burden, couldn’t establish
the temporal relationship because of its cross-sectional
nature.
Multiple studies in medicine have reported the negative
impact of the patients’ economic burden on treatment
compliance, including switching from more effective to less
effective therapy, not taking prescribed medications, fore-
going needed medical care, or reducing spending on daily
necessities, such as food and clothing [1-4,9,24,25]. In our
study, younger patients, those with lower educational level,patients whowere further out fromHCT, and thosewhowere
retired or on disability were more likely to exhibit such be-
haviors, similar to reports from other investigators. It is
known that treatment nonadherence leads to poor clinical
outcomes as well as higher health care utilization [8,9,26-
28]. Because HCT may result in chronic illness (due to
chronic GVHD and late medical complications) in a signiﬁ-
cant proportion of patients needing long-term medical
follow-up, it is possible that outcomes in HCT patients may
be inﬂuenced by treatment nonadherence, but more
research is needed to validate this observation.
A cross-sectional design, self-administered instrument,
and a modest response rate (56%) potentially resulting in
recall bias, self-selection, and reporting bias are limitations of
our study. It is possible that participants with higher ﬁnan-
cial burden may have been more driven to return the sur-
veys, though we did not ﬁnd any difference in the baseline
socioeconomic status based on the median household in-
come between the respondents and nonrespondents. Pa-
tients were accrued from 3 distinct tertiary care centers in
diverse geographic locations. However, as these sites have
similar institutional policies regarding the overall proﬁle of
the patients seen, they may be more similar to each other
than other transplantation programs, despite different
referral patterns and catchment areas. Some potential vari-
ables of interest were not captured, such as household size
and whether the primary bread winner or other family
member underwent transplantation. Despite the fact that
minority patients are over-represented in the poor/near poor
group, our study couldn’t detect an increased ﬁnancial
burden for them, perhaps due to limited power, given the
overall low number of racial/ethnic minority patients [29].
Other important associations may also have gone undetected
in our analysis because of limited number of respondents
and small numbers in some categories. We also acknowledge
that certain types of nonadherence may be more important
than others in inﬂuencing overall outcomes, but our ques-
tionnaire did not capture this in detail. We also did not
include any questions pertaining to patients’ communication
with a health care provider about ﬁnancial concerns and its
impact on their overall ﬁnancial experience or their decision-
making about care, based on costs. Finally, future studies are
needed to reﬁne and evaluate the validity, reliability,
Table 4
Risk Factors for Objective Financial Burden
Variable Unadjusted
OR (95% CI)
P
Value
Adjusted
OR (95% CI)*
P
Value
Age (per 5-yr increase) .9 (.86-1.04) .28 .8 (.7-.97) .0009
Current employment
Retired/disability 1 (ref) 1 (ref)
Employed .3 (.18-.5) <.0001 .32 (.18-.5) .0004
Unemployed .9 (.3-2.8) .9 1.3 (.3-6.2) .77
Current physical/mental functioning
PCS-12 < 40 3.9 (2.26.8) <.001 3.02 (1.6-5.9) .001
MCS-12 < 40 4.6 (2.2-9.8) <.001 3.5 (1.4-8.5) .006
Gender
Male 1 (ref)
Female 1.05 (.6-1.7) .8
Disease
Nonmalignant 1 (ref)
Acute leukemia 1.04 (.3-3.4) .94
Lymphoma/myeloma .8 (.2-2.9) .78
MDS/MPN and CML .67 (.2-2.2) .5
Disease risk at HCT
Nonmalignant 1 (ref)
Low 1.07 (.3-3.5) .9
Intermediate .8 (.2-2.58) .7
High .6 (.17-2.6) .5
Transplantation type
Unrelated 1 (ref)
Related .9 (.6-1.5) .84
Conditioning
Reduced intensity 1 (ref)
Myeloablative .8(.5-1.3) .36
H/O Acute GVHD
(grade II-IV)
1.5 (.7-3.6) .3
H/O Chronic GVHD .6 (.5-1.2) .2
Education
Four-yr degree or
higher
1 (ref)
High school or less .2 (.97-4.4) .05
Some college/
associate degree
1.4 (.8-2.8) .2
Time from transplantation
<1 yr 1 (ref)
1-3 yr .7 (.4-1.5) .42
>3 yr .9 (.4-2) .84
Race/ethnicity
Hispanic 1 (ref)
Non-Hispanic white .6 (.14-3) .58
Non-white .6 (.1-4) .64
OR indicates odds ratio; CI, conﬁdence interval; PCS, physical component
score; MCS, mental component score; H/O, history of.
* Variables with P value <.15 were included in the ﬁnal model.
Table 5
Risk Factors for Treatment Nonadherence due to Concern about Medical
Costs
Variable Unadjusted
OR (95% CI)
P
Value
Adjusted
OR (95% CI)*
P
Value
Age (per 5-yr increase) .83 (.75-.93) .001 .82 (.6-.9) .0009
Education
Four-yr degree or
higher
1 (ref) 1 (ref)
High school or less 3.9 (1.8-8.6) .0006 5 (1.7-15) .003
Some college/
associate degree
2.09 (1.13-3.8) .02 1.5 (.6-3.5) .3
Current employment
Retired/disability 1 (ref) 1 (ref)
Employed .5 (.2-.9) .03 .4 (.2- 1.0) .06
Unemployed 1.3 (.4-4.1) .66 1.8 (.3-8.7) .44
Current physical/mental functioning
PCS-12 < 40 2.5 (1.36-4.6) .003 2.3 (.97-5.5) .057
MCS-12 < 40 2.9 (1.5-5.7) .002
Time from transplantation
<1 yr 1 (ref) 1 (ref)
1-3 yr 1.04 (.5-2.3) .92 1.8 (.5-5.8) .29
>3 yr 2.2 (.9-5.09) .07 3.2 (.95-10.7) .059
Current household income
>$2000 per mo 1 (ref)
<$2000 per mo 5.2 (2.9-9.2) <.001
Gender
Male 1 (ref)
Female 1.7 (1.03-2.9) .036
Disease
Nonmalignant 1 (ref)
Acute leukemia 1.3 (.3-4.6) .66
Lymphoma/myeloma .87 (.2-3.2) .83
MDS/MPN and CML .9 (.2-3.3) .88
Disease risk
Nonmalignant 1 (ref)
Low 1.2 (.3-4.2) .78
Intermediate .89 (.25-3.17) .86
High 1.7 (.4-7.1) .44
Transplantation type
Unrelated 1 (ref)
Related 1.13 (.68-1.9) .62
Conditioning
Reduced intensity 1 (ref)
Myeloablative 1.9 (1.1-3.1) .02
H/O Acute GVHD
(grade II-IV)
1.9 (.74-4.9) .18
H/O Chronic GVHD 1.02 (.5-1.9) .94
Race/ethnicity
Hispanic 1 (ref)
Non-Hispanic white .4 (.08-1.7) .2
Non-white .88 (.13-5.6) .89
* Variables with P value <.15 were included in the ﬁnal model.
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assessing the ﬁnancial burden.
Notwithstanding these limitations, the study is an
exploratory analysis to describe the ﬁnancial experiences of
allogeneic HCT patients, and demonstrates the high degree of
ﬁnancial burden on patients and their families, even in this
highly insured group. It also indicates the need for health
care providers taking care of HCT patients to recognize
vulnerable groups of patients at high risk for ﬁnancial
toxicity and deleterious health behaviors as a result of it. This
underscores the importance of discussing such concerns
with patients at frequent time points before and after HCT.
Helping the patients understand the risks of treatment
nonadherence and connecting them to appropriate sources
of support can be a part of the “teachable moment” [30] that
allogeneic HCT provides for patients, especially those with
lower literacy levels. Some health care decisions on the basis
of cost may be acceptable if contemplated with input from
medical professionals, who can help balance ﬁnancial and
medical considerations.Moriates et al. have recently suggested simple steps “to do
no ﬁnancial harm,” while providing optimum “patient-
centered care” [31]. The increasing importance of this aspect
of cancer treatment has been realized by the policy makers,
too. The Affordable Care Act has provisions that may
decrease the cost burden for cancer, as well as HCT, patients,
such as the elimination of lifetime caps, prohibition of in-
surance companies’ ability to deny insurance on the basis of
pre-existing conditions, and the provision of universal health
coverage. In addition, by eliminating cost sharing for pre-
ventive practices, limiting OOP expenses, and narrowing the
Medicare part D coverage gap, the Affordable Care Act may
decrease the ﬁnancial burden on HCT patients and improve
treatment adherence.
There is a need for collecting information about the tra-
jectory of ﬁnancial burden, starting with diagnosis of the
hematological malignancy in a standardized fashion, pa-
tients’ perceptions of reasons for their ﬁnancial distress, and
N. Khera et al. / Biol Blood Marrow Transplant 20 (2014) 1375e1381 1381assessing tangible support mechanisms that would help
decrease ﬁnancial burden. Future research should also
include exploration of patients’ communication with health
care providers about ﬁnancial concerns, whether cost con-
cerns inﬂuence their treatment decision-making, and how
their overall ﬁnancial experience with HCT affects their long-
term health. This may help design studies evaluating in-
terventions to address these concerns, so that we can
continue to improve the outcomes of patients with hema-
tological disorders without causing excessive ﬁscal distress
and catastrophic socioeconomic consequences.
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